GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » PS Ratio

The Medicines Co (The Medicines Co) PS Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, The Medicines Co's share price is $84.90. The Medicines Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00. Hence, The Medicines Co's PS Ratio for today is .

The historical rank and industry rank for The Medicines Co's PS Ratio or its related term are showing as below:

MDCO's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.17
* Ranked among companies with meaningful PS Ratio only.

The Medicines Co's Revenue per Sharefor the three months ended in Sep. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00.

Back to Basics: PS Ratio


The Medicines Co PS Ratio Historical Data

The historical data trend for The Medicines Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co PS Ratio Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 8.50 16.76 43.95 230.60

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.30 230.60 - - -

Competitive Comparison of The Medicines Co's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Medicines Co's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where The Medicines Co's PS Ratio falls into.



The Medicines Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

The Medicines Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=84.90/0
=

The Medicines Co's Share Price of today is $84.90.
The Medicines Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


The Medicines Co  (NAS:MDCO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


The Medicines Co PS Ratio Related Terms

Thank you for viewing the detailed overview of The Medicines Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010

The Medicines Co (The Medicines Co) Headlines

From GuruFocus

David Einhorn's Greenlight Buys NeuBase Therapeutics Stake

By Holly LaFon Holly LaFon 07-17-2019

Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares

By GuruFocus Research GuruFocus Editor 03-02-2011